Topic:

Pipeline

Latest Headlines

Latest Headlines

BioDelivery tanks as its pain gel comes up short in Phase III

BioDelivery Sciences' in-development pain gel failed to meet its main goal in a late-stage trial, a surprise turn for the company as it looked forward to an FDA submission.

Novo Nordisk speeds back to the FDA with its once-rejected insulin

After a surprise FDA rejection sent it back to the drawing board in 2013, Novo Nordisk is finally ready to resubmit Tresiba, a long-acting insulin with blockbuster potential.

Genfit's NASH drug flunks Phase II, but management sees a silver lining

Genfit's in-development drug for a pervasive liver disease failed to beat placebo in a midstage trial, but the company, undaunted, is setting sights on late-stage studies with eyes on what could be a blockbuster market.

Blueprint plots a $100M IPO for its precision medicine platform

Cambridge, MA's Blueprint Medicines is lining up to raise $100 million in an IPO to advance a stable of personalized cancer treatments and build out its pipeline.

Novartis, Lilly lead a $44M round for rare disease biotech Aeglea

Austin, Texas, biotech Aeglea Biotherapeutics raised $44 million in Series B cash to bankroll its enzyme-replacement therapy for a rare metabolic disorder, with Eli Lilly and Novartis leading the round.

FDA removes the brakes on Pfizer and Lilly's pain drug

A once-halted pain candidate from partners Pfizer and Eli Lilly now has the green light to resume late-stage testing, as the FDA has lifted a clincal hold tied to some serious safety concerns for the whole class of drugs.

MEI's second go at cancer R&D flunks a Phase II MDS trial

MEI Pharma's lead candidate failed to meet its primary goal in a Phase II study on myelodysplastic syndrome, a rare bone marrow disorder that often develops after cancer treatment, sending the biotech trawling for a positive spin on the data.

AstraZeneca's rosy pipeline promise runs into harsh realities in oncology

AstraZeneca's ambitious goal of boosting sales by 75% by 2023 relies heavily on its work in the high-profile field of immuno-oncology, but changing winds and rivals' successes might make it hard for the U.K. drugmaker to follow through on those promises.

Biogen's Alzheimer's drug impresses in early study with Phase III on the way

Biogen Idec's heavily scrutinized Alzheimer's disease program came through with some positive early results, improving cognition and blasting away brain plaques in a small study many see as a validation of the company's ambitions in the field.

Prothena rockets up with early data on a Roche-partnered Parkinson's drug

In a small study, an early-stage Parkinson's treatment from partners Prothena and Roche reduced levels of a protein with ties to the memory-destroying disease, sending the former company's shares up about 40%.